UNCY
Unicycive Therapeutics, Inc.
$3.89
-1.27%
2026-10-23
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
Key Fundamentals
Forward P/E
2.82
EPS (TTM)
$-1.75
ROE
-101.1%
Profit Margin
0.0%
Debt/Equity
1.26
Price/Book
2.46
Beta
1.78
Market Cap
$128.6M
Avg Volume (10D)
861K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$5.85
60D Low
$3.35
Avg Volume
872K
Latest Close
$3.89
Get breakout alerts for UNCY
Sign up for Breakout Scanner to receive daily notifications when UNCY triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Unicycive Therapeutics, Inc. (UNCY) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors UNCY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. UNCY operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.